Here, we investigated the in vivo function and mechanistic underpinnings of combination treatment of PTEN-deficient GBM using the S6K1 inhibitor LY-2584702 and the AXL inhibitor BMS-777607. The gene discussed is RPS6KB1; the disease is glioblastoma.